Compromised function of natural killer cells in acute and chronic viral hepatitis

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1362-1373

  Lunemann, Sebastian ^a,b   Malone, David F G ^b   Hengst, Julia ^a,b   Port, Kerstin ^a   Grabowski, Jan ^a   Deterding, Katja ^a   Markova, Antoaneta ^a   Bremer, Birgit ^a   Schlaphoff, Verena ^a   Cornberg, Markus ^a   Manns, Michael P ^a   Sandberg, Johan K ^b   Ljunggren, Hans Gustaf ^b   Björkström, Niklas K ^b   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HBV; HCV; HDV; NK cells; viral hepatitis

Indexed keywords

HBV; HCV; HDV; NK CELLS; VIRAL HEPATITIS;

ACUTE DISEASE; ADULT; AGED; ANTIGENS, CD; CASE-CONTROL STUDIES; FEMALE; HEPATITIS, CHRONIC; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; YOUNG ADULT;

EID: 84898912215     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit561     Document Type: Article

References (50)

1. EASL. Clinical practice guidelines HBV: EASL-European association for the study of the liver. J Hepatol 2012; 57:167-85
2. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661-2
3. EASL. Clinical practice guidelines HCV: EASL-European association for the study of the liver. J Hepatol 2011; 55:245-64
4. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 2013; 57:1333-42
5. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7:31-40
6. Protzer U, Maini MK, Knolle PA. Living in the liver: Hepatic infections. Nat Rev Immunol 2012; 12:201-13
7. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J Clin Invest 2009; 119:1745-54
8. Bertoletti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: Immunological controversies. Antivir Ther 2010; 15:15-24
9. Schlaphoff V, Lunemann S, Suneetha PV, et al. Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+T cells. PLoS Pathog 2011; 7:e1002045
10. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61:i6-17
11. Klenerman P, Thimme R. T cell responses in hepatitis C: The good, the bad, and the unconventional. Gut 2012; 61:1226-34
12. Grabowski J, Wedemeyer H. Hepatitis delta: Immunopathogenesis and clinical challenges. Dig Dis 2010; 28:133-8
13. Grabowski J, Yurdaydin C, Zachou K, et al. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon α treatment. Liver Int 2011; 31:1395-405
14. Doherty DG, Norris S, Madrigal-Estebas L, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999; 163:2314-21
15. Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011; 11:658-71
16. Caligiuri MA. Human natural killer cells. Blood 2008; 112:461-9
17. Bryceson YT, Chiang SC, Darmanin S, et al. Molecular mechanisms of natural killer cell activation. J Innate Immun 2011; 3:216-26
18. Amadei B, Urbani S, Cazaly A, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 2010; 138:1536-45
19. Stegmann KA, Björkström NK, Veber H, et al. Interferon-Alphainduced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010; 138:1885-97
20. Golden-Mason L, Castelblanco N, O'Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J Virol 2007; 81:9292-8
21. Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137:1289-300
22. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872-4
23. Dring MM, Morrison MH, Guinan KJ, et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci 2011; 108:5736-41
24. Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006; 55:869-77
25. Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137:1151-60., 1160.e1-7
26. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cellmediated liver damage. J Exp Med 2007; 204:667-80
27. Zhang Z, Zhang S, Zou Z, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 2011; 53:73-85
28. Golden-Mason L, Bambha KM, Cheng L, et al. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 2011; 54:1559-69
29. Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis. B J Hepatol 2011; 54:209-18
30. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195: 43-9
31. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195:35-41
32. Yoon JC, Shiina M, Ahlenstiel G, Rehermann B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 2009; 49:12-21
33. Crotta S, Brazzoli M, Piccioli D, Valiante NM, Wack A. Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection. J Hepatol 2010; 52:183-90
34. Peppa D, Gill US, Reynolds G, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 2012; 210:99-114
35. Deterding K, Wiegand J, Gruner N, et al. The German hep-net acute hepatitis C cohort: Impact of viral and host factors on the initial presentation of acute hepatitis C virus infection Z. Gastroenterol 2009; 47:531-40
36. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 2010; 52:514-22
37. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-31
38. Yurdaydin C, Wedemeyer H, Caruntu FA, et al. Pegylated-interferon- α-2a plus tenofovir or placebo for the treatment of hepatitis delta: First results of the HIDIT-2 study. AASLD 2012; 56:203A
39. Stegmann KA, Bjorkstrom NK, Ciesek S, et al. Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis 2012; 205:1351-62
40. Bjorkstrom NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853-64
41. Björkström NK, Lindgren T, Stoltz M, et al. Rapid expansion and longterm persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011; 208:13-21
42. Golden-Mason L, Rosen HR. Natural killer cells: Primary target for hepatitis C virus immune evasion strategies? Liver Transpl 2006; 12:363-72
43. Mondelli MU, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: Facts and controversies. Eur J Clin Invest 2010; 40:851-63
44. Alter G, Jost S, Rihn S, et al. Reduced frequencies of NKp30+NKp46+, CD161+ and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol 2011; 55:278-88
45. Ercilla MG, Barrera JM, Jove J, et al. Influence of HBV replication and delta agent superinfection on T cell subsets and killer (leu 7+) in chronic hepatitis B virus infection. J Hepatol 1986; 3:378-83
46. Actis GC, Maran E, Rosina F, et al. Natural killer response to exogenous interferon in delta hepatitis: Boost or depression defined within the first week of therapy. Digestion 1987; 37:51-8
47. Actis GC, Maran E, Bonino F, et al. Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: Relationship with the state of viral infection and with the early clinical response. J Biol Regul Homeost Agents 1987; 1:45-50
48. Varchetta S, Mele D, Mantovani S, et al. Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 2012; 56:841-9
49. Gur C, Doron S, Kfir-Erenfeld S, et al. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 2012; 61:885-93
50. Björkström NK, Svensson A, Malmberg KJ, Eriksson K, Ljunggren HG. Charaterization of natural killer cell phenotype and function during recurrent human HSV-2 infection. PLoS One 2011; 6:e27664.